Compare PTCT & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTCT | ESNT |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.9B |
| IPO Year | 2006 | 2013 |
| Metric | PTCT | ESNT |
|---|---|---|
| Price | $72.06 | $69.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $80.65 | $67.29 |
| AVG Volume (30 Days) | ★ 1.2M | 500.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | ★ 264.48 | 0.73 |
| EPS | 0.90 | ★ 3.89 |
| Revenue | $264,734,000.00 | ★ $1,260,935,000.00 |
| Revenue This Year | N/A | $1.12 |
| Revenue Next Year | $17.70 | $3.37 |
| P/E Ratio | $80.71 | ★ $17.55 |
| Revenue Growth | ★ 36.19 | 1.45 |
| 52 Week Low | $47.94 | $55.34 |
| 52 Week High | $90.87 | $70.00 |
| Indicator | PTCT | ESNT |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 63.75 |
| Support Level | $68.16 | $59.76 |
| Resistance Level | $72.09 | N/A |
| Average True Range (ATR) | 2.96 | 1.68 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 50.82 | 83.14 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.